Treatment of central nervous system disorders by intranasal administration of immunoglobulin G
View Patent ↗The present invention provides, among other aspects, methods and compositions for treating a central nervous system (CNS) disorder by delivering a therapeutically effective amount of a composition of pooled human immunoglobulin G (IgG) to the brain via intranasal administration of the composition directly to the olfactory epithelium of the nasal cavity. In particular, methods and compositions for treating Alzheimer's disease are provided.
1. A method for treating Alzheimer's disease in a subject in need thereof, the method comprising:
delivering a therapeutically effective amount of a composition comprising pooled human immunoglobulin G (IgG) to the brain of the subject,
wherein delivering the composition to the brain comprises intranasally administering the composition to the upper third of the nasal cavity of the subject,
wherein at least 40% of the pooled human IgG administered to the subject contacts the nasal epithelium located in the upper third of the nasal cavity of the subject.
2. The method of claim 1 , wherein intranasal administration of the composition comprises directed administration of a liquid aerosol of the composition to the nasal epithelium located in the upper third of the nasal cavity of the subject.
3. The method of claim 2 , wherein at least 40% of the pooled human IgG administered to the subject contacts the nasal epithelium located in the upper third of the nasal cavity of the subject.
4. The method of claim 2 , wherein at least 50% of the pooled human IgG administered to the subject contacts the nasal epithelium located in the upper third of the nasal cavity of the subject.
5. The method of claim 2 , wherein at least 60% of the pooled human IgG administered to the subject contacts the nasal epithelium located in the upper third of the nasal cavity of the subject.
6. The method of claim 2 , wherein at least 70% of the pooled human IgG administered to the subject contacts the nasal epithelium located in the upper third of the nasal cavity of the subject.
7. The method of claim 1 , wherein intranasal administration of the composition comprises directed administration of a powder aerosol of the composition to the nasal epithelium located in the upper third of the nasal cavity of the subject.
8. The method of claim 7 , wherein at least 40% of the pooled human IgG administered to the subject contacts the nasal epithelium located in the upper third of the nasal cavity of the subject.
9. The method of claim 7 , wherein at least 50% of the pooled human IgG administered to the subject contacts the nasal epithelium located in the upper third of the nasal cavity of the subject.
10. The method of claim 7 , wherein at least 60% of the pooled human IgG administered to the subject contacts the nasal epithelium located in the upper third of the nasal cavity of the subject.
11. The method of claim 7 , wherein at least 70% of the pooled human IgG administered to the subject contacts the nasal epithelium located in the upper third of the nasal cavity of the subject.
12. The method of claim 1 , wherein the composition comprising pooled human IgG consists essentially of pooled human IgG and an amino acid selected from the group consisting of glycine, histidine, and proline.
13. The method of claim 1 , wherein the composition comprising pooled human IgG is an aqueous composition comprising:
(a) from 10 mg/mL to 250 mg/mL pooled human IgG; and
(b) from 50 mM to 500 mM glycine.
14. The method of claim 13 , wherein the pH of the composition is from 4.0 to 6.0.
15. The method of claim 13 , wherein the pH of the composition is from 6.0 to 7.5.
16. The method of claim 1 , wherein the composition comprising pooled human IgG is a dry powder composition prepared from an aqueous solution comprising:
(a) from 10 mg/mL to 250 mg/mL pooled human IgG; and
(b) from 50 mM to 500 mM glycine.
17. The method of claim 16 , wherein the dry powder composition is prepared from an aqueous solution having a pH of from 4.0 to 6.0.
18. The method of claim 16 , wherein the dry powder composition is prepared from an aqueous solution having a pH of from 6.0 to 7.5.
19. The method of claim 1 , wherein the method comprises intranasally administering to the subject a dose of from 0.08 mg to 100 mg pooled human IgG per kg body weight of the subject (mg IgG/kg).
20. The method of claim 1 , wherein the method comprises intranasally administering to the subject a fixed dose of from 50 mg to 10 g pooled human IgG.
21. The method of claim 1 , wherein the method comprises intranasally administering to the subject a dose of pooled human IgG at least twice monthly.
22. The method of claim 1 , wherein the composition comprising pooled human IgG comprises at least 0.1% anti-amyloid β IgG.
23. The method of claim 1 , further comprising administering a known second therapy for Alzheimer's disease to the subject in need thereof.
24. The method of claim 23 , wherein the second therapy for Alzheimer's disease comprises administration of a cholinesterase inhibitor.
25. The method of claim 24 , wherein the cholinesterase inhibitor is selected from the group consisting of donepezil, rivastigmine, galantamine, and tacrine.
26. The method of claim 23 , wherein the second therapy for Alzheimer's disease comprises administration of an inhibitor of NMDA-type glutamate receptor.
27. The method of claim 26 , wherein the inhibitor of NMDA-type glutamate receptor is memantine.
28. The method of claim 1 , wherein intranasal administration of the composition comprises directed administration of the composition to the olfactory epithelium of the nasal cavity of the subject.
29. The method of claim 1 , wherein at least 50% of the pooled human IgG administered to the subject contacts the nasal epithelium located in the upper third of the nasal cavity of the subject.
30. The method of claim 1 , wherein at least 60% of the pooled human IgG administered to the subject contacts the nasal epithelium located in the upper third of the nasal cavity of the subject.
31. The method of claim 1 , wherein at least 70% of the pooled human IgG administered to the subject contacts the nasal epithelium located in the upper third of the nasal cavity of the subject.